CSIMarket Company Name, Ticker, Industry, else..
 
Nephros Inc   (NEPH)
Other Ticker:  
 
 
Price: $1.5000 $0.04 2.740%
Day's High: $1.535 Week Perf: 0.00
Day's Low: $ 1.45 30 Day Perf: -19.45 %
Volume (M): 12 52 Wk High: $ 4.04
Volume (M$): $ 18 52 Wk Avg: $2.36
Open: $1.47 52 Wk Low: $1.43



 Market Capitalization (Millions $) 16
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) 13
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Nephros Inc
Nephros Inc is a medical technology company that specializes in developing and marketing filtration products for the medical and commercial markets. The company focuses on designing products that remove harmful particles, bacteria, viruses, and other contaminants from water and other fluids, with the goal of improving the quality of life for individuals with kidney and other chronic diseases. Nephros Inc offers a range of filtration systems, including portable hemodiafiltration machines used in dialysis centers, ultrafilters for water purification, and filters for medical applications. The company is committed to innovative solutions that provide effective and efficient filtration, ensuring the safety and well-being of its customers.


   Company Address: 380 Lackawanna Place South Orange 7079 NJ
   Company Phone Number: 343-5202   Stock Exchange / Ticker: NASDAQ NEPH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Nephros Inc

Record Revenue Growth in Fiscal Fourth Quarter of 2023 for Nephros Inc

As a Wall Street journalist, it is important to analyze the financial performance of companies like Nephros Inc in order to provide valuable insights to investors.
For the fiscal fourth quarter of 2023, Nephros Inc reported a loss of $0.06 per share, which was an improvement from the loss of $0.16 per share in the same period a year prior. However, compared to the previous financial reporting period, the company's loss per share increased from $0.02. Despite the mixed results in terms of earnings, Nephros Inc saw a significant increase in revenue, with a growth rate of 67.971% to $3.44 million from $2.05 million in the same period last year.
The company also reported a net loss of $0.654 million for the fiscal fourth quarter of 2023, compared to a loss of $1.527 million in the same period a year ago. While Nephros Inc's stockpiles increased to $2.5 million, it is worth noting that this level remains below the previous year's level of $3.2 million. The build-up in accounts receivable is a positive sign of rising demand, with accounts receivable valued at $1.5 million, higher than in the preceding quarter.
Looking at the full-year results for 2023, Nephros Inc reported revenue of $13.41 million and a net loss of $1.58 million. The company managed to decrease its loss per share to $0.15 from $0.73 in the previous fiscal year, while revenue surged by 34.39% from $9.98 million a year prior.
Nephros Inc

Nephros Inc. Shatters Records, Achieving Epic Results in Financial Period Ending Sep 30 2023

In a recent financial time-frame, Nephros Inc has shown promising results in the stock market. The company has successfully decreased its loss per share from $-0.31 to $-0.02, indicating a significant improvement from the previous year. Furthermore, the company's earnings per share (EPS) also saw a positive change, going from $-0.04 in the previous quarter to $-0.02.
Nephros Inc's revenue has experienced a remarkable increase of 32.586% from $2.41 million to $3.19 million compared to the corresponding quarter a year ago. Additionally, the company's revenue sequentially surged by 3.735% from $3.08 million. This growth in revenue is particularly impressive as it outperformed many other companies in the Medical Equipment & Supplies industry.
Nephros Inc

Nephros Inc's Revenue Surges in Q2 2023, but Shortfall Persists Despite Advance

Nephros Inc, a leader in the Medical Equipment & Supplies sector, has shown promising financial results for the span ending June 30, 2023. Despite reporting a loss of $0.04 per share, it is a significant improvement from the loss of $0.12 per share in the same quarter a year ago. Additionally, compared to the previous quarter, the company has reduced its deficit from $0.03 per share. While it is important to highlight the company's losses, it is evident that Nephros Inc is moving towards a more profitable path.
The company's revenue growth is a notable accomplishment, with a 6.761% increase to $3.08 million from $2.88 million in the corresponding quarter last year. However, Nephros Inc experienced a sequential revenue decline of -16.716% from $3.70 million. Despite this decline, the company outperformed its sector contemporaries, who had an average top-line growth of 4.51% during the same period. This impressive performance indicates Nephros Inc's ability to generate revenue, even in a challenging market.
Nephros Inc

Nephros Inc Shows Remarkable Turnaround, Achieving Deficit Redemption in Recent Fiscal Period

Nephros Inc is a medical device company that specializes in providing solutions for patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its products aim to improve the quality of life for individuals suffering from CKD/ESRD by offering safe and effective water filtration systems for dialysis patients and hospitals.
The company's most recent financial reporting period shows significant improvements in its financial performance. Nephros Inc reported a decrease in its loss per share from $-0.11 to $-0.03, reflecting a positive growth trend in earnings per share. Additionally, the company experienced a notable surge in revenue by 33.707%, generating $3.70 million compared to $2.77 million during the same period a year ago. Sequentially, Nephros Inc's revenue also grew exponentially, reporting an 80.782% jump from $2.05 million.






Nephros Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com